http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8023625

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't
endingPage 710
issn 1533-4406
0028-4793
issueIdentifier 8
pageRange 699-710
publicationName The New England journal of medicine
startingPage 699
bibliographicCitation Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22;369(8):699–710. doi: 10.1056/nejmoa1215734. PMID: 23964932.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_80ffd14439be79a77a6244ec05d06cca
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9f20f0daa7c101e01de918a79c59dbe4
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_715c1f7596e51fb727b396e41b4cb2c3
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1b93fae0beec42ab44d032e2c7545f52
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9ec02e5029a0dba6f184591d700385d3
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5c52107cdb96d06ff972ed9fa46b49e7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4193c33d503685670e88c6e5e71748e5
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c2589d5de20e3b93859dc9ef3e570d70
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9746e1fc3f17f95f606eefd4943667ce
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_83908594169196f6f7f9c6d53aea3d96
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_561ebc7713e6daaa14b41786a0a9fbbe
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_282b76cebd09e16bb8ab321e33b3f76a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1e6154024ae87f73220f62e23506c957
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b97c912442035ecbdbfc1fceac1cf8d0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7fa4366a129ed78ab1fbf6a8a6e337d8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4830f23d8245019050af89b098ef8933
date 2013-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1056/nejmoa1215734
https://pubmed.ncbi.nlm.nih.gov/23964932
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5985
https://portal.issn.org/resource/ISSN/0028-4793
https://portal.issn.org/resource/ISSN/1533-4406
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
discusses http://id.nlm.nih.gov/mesh/M0024497
http://id.nlm.nih.gov/mesh/M0556300
http://id.nlm.nih.gov/mesh/M0539116
http://id.nlm.nih.gov/mesh/M0009322
http://id.nlm.nih.gov/mesh/M0011171
http://id.nlm.nih.gov/mesh/M0194830
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D003093Q000188
http://id.nlm.nih.gov/mesh/D061067Q000627
http://id.nlm.nih.gov/mesh/D016023Q000276
hasSubjectTerm http://id.nlm.nih.gov/mesh/D060828
http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D007166Q000627
http://id.nlm.nih.gov/mesh/D061067Q000493
http://id.nlm.nih.gov/mesh/D004334
http://id.nlm.nih.gov/mesh/D004311
http://id.nlm.nih.gov/mesh/D000328
http://id.nlm.nih.gov/mesh/D060046
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D005938Q000627
http://id.nlm.nih.gov/mesh/D061067Q000009
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D000368
http://id.nlm.nih.gov/mesh/D004359
http://id.nlm.nih.gov/mesh/D016023Q000037
http://id.nlm.nih.gov/mesh/D008875
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7969
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7300

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID252166617

Total number of triples: 63.